The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

•MET amplification is one of the EGFR-independent mechanisms of EGFR TKI resistance.•Combined EGFR-TKI and crizotinib achieved an overall response rate of 81.8 % (9/11).•MET amplification acquired at EGFR-TKI resistance are actionable.•EGFR-TKI/crizotinib combination is effective in targeting MET-amplified, EGFR-mutant NSCLC.